Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Topline results expected in 1Q calendar year 2025Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weightData will inform and support the Company's obesity programs using novel,